Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause

Phase 3 Completed 325 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective in the treatment of moderate to severe vasomotor symptoms associated with menopause.

Timeline

Start: 2005-10
Primary completion: —
Completion: 2007-02

Publications

Archer DF, Freeman EW, Komm BS, Ryan KA, Yu CR, Mirkin S, Pinkerton JV. Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials. J Womens Health (Larchmt). 2016 Nov;25(11):1102-1111. doi: 10.1089/jwh.2015.5558. Epub 2016 Sep 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bazedoxifene	Other / unclassified	20 mg	—
Subject	conjugated estrogens	Other / unclassified	0.45 mg	—
Subject	conjugated estrogens	Other / unclassified	0.625 mg	—

Indications

No indication recorded.